ESSA Pharma
Yahoo Finance • 2 days ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EPIX
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of securities of ESSA Pharma Inc. (NASDAQ: EPIX)... Full story
Yahoo Finance • 3 days ago
Class Action Filed Against ESSA Pharma Inc. (EPIX) Seeking Recovery for Investors – Contact Levi & Korsinsky
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to r... Full story
Yahoo Finance • 4 days ago
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit – EPIX
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during the class period listed are encouraged to co... Full story
Yahoo Finance • 4 days ago
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ESSA Pharma between... Full story
Yahoo Finance • 5 days ago
ESSA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ESSA Pharma Inc. and Encourages Investors to Contact the Firm
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against ESSA Pharma Inc. (“ESSA” or the “Company”) (NASDAQ... Full story
Yahoo Finance • 5 days ago
EPIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. (“ESSA” or “th... Full story
Yahoo Finance • 5 days ago
EPIX Investor Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against ESS Pharma Inc.
SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired ESSA Pharma Inc. (NASDAQ: EPIX) securities between Decemb... Full story
Yahoo Finance • 6 days ago
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against ESSA Pharma Inc. (EPIX)
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Wisconsin on behalf of all persons or e... Full story
Yahoo Finance • 6 days ago
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of ESSA Pharma Inc. (EPIX) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
ATLANTA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against ESSA Pharma Inc. (“ESSA” or the “Company”) (NASDAQ: EPIX). The lawsuit alleges that Defendants made materially false and/or misleading s... Full story
Yahoo Finance • last year
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination wi... Full story
Yahoo Finance • last year
ESSA Pharma to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Nov. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of p... Full story
Yahoo Finance • 2 years ago
Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors
Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effec... Full story
Yahoo Finance • 2 years ago
ESSA Pharma to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 10, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of pro... Full story
